A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Latest Information Update: 20 Feb 2024
At a glance
- Drugs CC-92328 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 13 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2023 Planned primary completion date changed from 11 Nov 2025 to 1 Jul 2025.
- 11 Oct 2022 Planned End Date changed from 10 Feb 2026 to 21 Jun 2026.